Aprotinin. An update of its pharmacology and therapeutic use in open heart surgery and coronary artery bypass surgery

Drugs

Volumn 57, Issue 2, 1999, Pages 233-260

  Peters, Dene C ^a   Noble, Stuart ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENT; APROTININ; CREATININE; DESMOPRESSIN; HEPARIN; KALLIKREIN; METHYLPREDNISOLONE; PLASMIN; PROTAMINE; THROMBOPLASTIN; TRANEXAMIC ACID; TRYPSIN;

ANAPHYLAXIS; ANTICOAGULATION; ARTICLE; BLEEDING; BLOOD CLOTTING TIME; BLOOD TRANSFUSION; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; COST EFFECTIVENESS ANALYSIS; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG COST; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; FIBRINOLYSIS; HEART INFARCTION; HEMOSTASIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY DISEASE; META ANALYSIS; METHODOLOGY; NONHUMAN; OPEN HEART SURGERY; PARTIAL THROMBOPLASTIN TIME; RASH; STROKE; THROMBOCYTE FUNCTION; URTICARIA; VEIN GRAFT; VEIN OCCLUSION;

APROTININ; CORONARY ARTERY BYPASS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HEMOSTATICS; HUMANS; RISK FACTORS; THORACIC SURGERY;

EID: 0033009619     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199957020-00015     Document Type: Article

References (124)

1. Davis R, Whittington R. Aprotinin: a review of its pharmacology and therapeutic efficacy in reducing blood loss associated with cardiac surgery. Drugs 1995 Jun; 49: 954-83
2. Boisclair MD, Lane DA, Philippou H, et al. Mechanisms of thrombin generation during surgery and cardiopufmonary bypass. Blood 1993 Dec 1; 82 (11): 3350-7
3. Robert S, Wagner BKJ, Boulanger M, et al. Aprotinin. Ann Pharmacother 1996; 30 (4): 372-80+407-8
4. Pakalnis R, O'Hara IB, Campbell FW. Prevention and treatment of post-cardiopulmonary bypass bleeding. Curr Opin Anaesth 1995; 8 (1): 49-55
5. John LCH, Deverall PB. Current methods to reduce the adverse haematological consequences of cardiopulmonary bypass. Br J Clin Pract 1996; 50 (4): 203-6
6. McCarthy MW, Coley KC. Aprotinin for prophylaxis of blood loss. Ann Pharmacother 1994 Nov; 28: 1246-8
7. Levy JH, Bailey JM, Salmenperä M. Pharmacokinetics of aprotinin in preoperative cardiac surgical patients. Anesthesiology 1994 May; 80: 1013-8
8. Royston D. Aprotinin in patients having coronary artery bypass graft surgery. Curr Opin Cardiol 1995; 10 (6): 591-6
9. Royston D. Aprotinin therapy [editorial]. Br J Anaesth 1994 Dec; 73: 734-7
10. Dobkowski WB, Murkin JM. A risk-benefit assessment of aprotinin in cardiac surgical procedures. Drug Saf 1998 Jan; 18: 21-41
11. Royston D. Preventing the inflammatory response to open-heart surgery: the role of aprotinin and other protease inhibitors. Int J Cardiol 1996 Apr 26; 53 Suppl: S11-37
12. Blauhut B, Harringer W, Bettelheim P, et al. Comparison of the effects of aprotinin and tranexamic acid on blood loss and related variables after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1994 Dec; 108: 1083-91
13. Hayashida N, Isomura T, Sato T, et al. Effects of minimal-dose aprotinin on coronary artery bypass grafting. J Thorac Cardiovasc Surg 1997 Aug; 114: 261-9
14. Ray MJ, Marsh NA. Aprotinin reduces blood loss after cardiopulmonary bypass by direct inhibition of plasmin. Thromb Haemost 1997 Sep; 78: 1021-6
15. Lu H, Du Buit C, Soria J, et al. Postoperative hemostasis and fibrinolysis in patients undergoing cardiopulmonary bypass with or without aprotinin therapy. Thromb Haemost 1994 Sep; 72: 438-43
16. Mastroroberto P, Chello M, Zofrea S, et al. Suppressed fibrinolysis after administration of low-dose aprotinin: reduced level of plasmin-alpha(2)-plasmin inhibitor complexes and post-operative blood loss. Eur J Cardiothorac Surg 1995 Mar; 9: 143-5
17. Spannagl M, Dietrich W, Beck A, et al. High dose aprotinin reduces prothrombin and fibrinogen conversion in patients undergoing extracorporeal circulation for myocardial revascularization. Thromb Haemost 1994 Jul; 72: 159-60
18. Dietrich W, Dilthey G, Spannagl M, et al. Influence of high-dose aprotinin on anticoagulation, heparin requirement, and celite- and kaolin-activated clotting time in heparin-pretreated patients undergoing open-heart surgery. Anesthesiology 1995 Oct; 83: 679-89
19. Menichetti A, Tritapepe L. Ruvolo G, et al. Changes in coagulation patterns, blood loss and blood use after cardiopulmonary bypass: aprotinin vs tranexamic acid vs epsilon aminocaproic acid. J Cardiovasc Surg 1996; 37 (4): 401-7
20. Boughenou F, Madi-Jebara S, Massonnet-Castel S, et al. Fibrinolytic inhibitors and the prevention of bleeding in cardiac valvular surgery: comparison of tranexamic acid and high dose aprotinin [in French]. Arch Mal Coeur Vaiss 1995 Mar; 88: 363-70
21. Casas JI, Zuazujausoro I, Mateo J, et al. Aprotinin versus desmopressin for patients undergoing operations with cardiopul monary bypass: a double-blind placebo-controlled study. J Thorac Cardiovasc Surg 1995 Oct; 110: 1107-17
22. Speekenbrink RGH, Wildevuur CRH, Sturk A, et al. Low-dose and high-dose aprotinin improve hemostasis in coronary operations. J Thorac Cardiovasc Surg 1996 Aug; 112: 523-30
23. Rossi M, Storti S, Martinelli L, et al. A pump-prime aprotinin dose in cardiac surgery: appraisal of its effects on the hemostatic system. J Cardiothorac Vasc Anesth 1997 Dec; 11: 835-9
24. Christensen U, Schiodt J. Effects of aprotonin on coagulation and fibrinolysis enzymes. Fibrinolysis Proteolysis 1997 Jul; 11: 209-14
25. Primack C, Walenga JM, Koza MJ, et al. Aprotinin modulation of platelet activation in patients undergoing cardiopulmonary bypass operations. Ann Thorac Surg 1996 Apr; 61: 1188-93
26. Ammar T, Sarier K, Vela-Cantos F. The effects of aprotinin and tranexamic acid on the platelet membrane GPIB receptor [abstract 60]. Anesth Analg 1997 Feb; 84 Suppl.
27. Kanbak G, Inal M, Alatas O, et al. Effect of high-dose aprotinin on plasma levels during cardiopulmonary bypass. Turk J Med Sci 1997; 27 (2): 175-7
28. Wahba A, Black G, Koksch V, et al. Aprotinin has no effect on platelet activation and adhesion during cardiopulmonary bypass. Thromb Haemost 1996 May; 75: 844-8
29. Boldt J, Zickmann B, Schindler E, et al. Influence of aprotinin on the thrombomodulin protein C system in pediatric cardiac operations. J Thorac Cardiovasc Surg 1994 May; 107: 1215-21
30. Wahba A, Philip A, Bauer MF, et al. The blood saving potential of vortex versus roller pump with and without aprotinin. Perfusion 1995; 10 (5): 333-41
31. Murkin JM. Cardiopulmonary bypass and the inflammatory response: a role for serine protease inhibitors? J Cardiothorac Vasc Anesth 1997; 11 (2) Suppl. 1: 19-23
32. Diego RP, Mihalakakos PJ, Hexum TD, et al. Methylprednisolone and full-dose aprotinin reduce reperfusion injury after cardiopulmonary bypass. J Cardiothorac Vasc Anesth 1997 Feb; 11: 29-31
33. Hill GE, Diego RP, Stammers AH, et al. Aprotinin enhances the endogenous release of interleukin-10 after cardiac operation. Ann Thorac Surg 1998 Jan; 65: 66-9
34. Hill GE, Pohorecki R, Alonso A, et al. Aprotinin reduces interleukin-8 production and lung neutrophil accumulation after cardiopulmonary bypass. Anesth Analg 1996 Oct; 83: 696-700
35. Mihalakakos P, Hofmann S, Hill GE. Steroids and full dose aprotinin, not half dose, reduce the possibility of reperfusion injury following CPB in humans [abstract]. Anesthesiology 1996 Sep; 85 Suppl.: abstr. 128
36. Ruggeroli AC, Carruthers RG, Pohorecki R, et al. Cardiopulmonary bypass-induced inflammation: steroids vs aprotinin [abstract]. Anesthesiology 1995 Sep; 83 Suppl: abstr.83
37. Tran T, Pohorecki R, Hofmann S, et al. The effect of aprotinin on anti-inflammatory cytokines following CPB [abstract]. Anesthesiology 1997 Sep; 87 Suppl.: Abstr.96
38. Hill GE, Alonso A, Spurzem JR, et al. Aprotinin and methyl- prednisolone equally blunt cardiopulmonary bypass-induced inflammation in humans. J Thorac Cardiovasc Surg 1995 Dec; 110: 1658-62
39. Alonso A, Galbraith TA, Spurzem JR, et al. The effect of 'pump prime only' aprotinin on neutrophil CDIIb upregulation during and following cardiopulmonary bypass in humans [abstract]. Chest 1996 Oct; 110 Suppl.: 204S
40. Seghaye MC, Duchateau J, Grabitz RG, et al. Influence of low-dose aprotinin on the inflammatory reaction due to cardiopulmonary bypass in children. Ann Thorac Surg 1996 Apr; 61: 1205-11
41. Ashraf S, Tian Y, Cowan D, et al. Low-dose aprotinin modifies hemostasis but not proinflammatory cytokinc release. Ann Thorac Surg 1997 Jan; 63: 68-73
42. Rao PS, Palazzo RS, Bocchieri KA, et al. Aprotinin protects against myocardial and oxidant formation and endothelial cell damage during open heart surgery. Ann N Y Acad Sci 1996; 793: 514-6
43. Broche VF, Suàrez AR, Olembe E, et al. Aprotinin effects related to oxidative stress in cardiosurgery with mechanical cardiorespiratory support (CMCS). Ann N Y Acad Sci 1996; 793: 521-4
44. Buchele S, Roberts T, Newland M, et al. Mechanism of aprotinin- induced reduction of airway nitric oxide during CPB [abstract]. Anesthesiology 1996 Sep; 85 Suppl.: abstr.129
45. Bruda NL, Hurlbert BJ, Hill GE. Aprotinin reduces nitric oxide production in vitro and vivo in a dose dependent manner [abstract]. Anesthesiology 1996 Sep; 85 Suppl.: abstr.130
46. Hill GE, Taylor JA, Robbins RA. Differing effects of aprotinin and -aminocaproic acid on cytokine-induced inducible nitric oxide synthase expression. Ann Thorac Surg 1997; 63 (1): 74-7
47. Hill GE, Robbins RA. Aprotinin but not tranexamic acid inhibits cytokine-induced inducible nitric oxide synthase expression. Anesth Analg 1997 Jun; 84: 1198-202
48. Szabó C, Southan GJ, Thiemermann C. Beneficial effects and improved survival in rodent models of septic shock with S-methylisothiourea sulfate, a potent and selective inhibitor of inducible nitric oxide synthase. Proc Natl Acad Sci U S A 1994 Dec; 91: 12472-6
49. Ungureanu-Longrois D, Balligand JL, Kelly RA, et al. Myocardial contractile dysfunction in the systemic inflammatory response syndrome: role of a cytokine-inducible nitric oxide synthase in cardiac myocytes. J Mol Cell Cardiol 1995 Jan; 27 (1): 155-67
50. Haywood GA, Tsao PS, Von der Leyen HE, et al. Expression of inducible nitric oxide synthase in human heart failure. Circulation 1996; 93: 1087-94
51. Szabolcs M, Michler RE, Yang X, et al. Apoptosis of cardiac myocytes during cardiac allograft rejection: relation to induction of nitric oxide synthase. Circulation 1996; 94: 1665-73
52. Bennett-Guerrero E, Sorohan JG, Howell ST, et al. Maintenance of therapeutic plasma aprotinin levels during prolonged cardiopulmonary bypass using a large-dose regimen. Anesth Analg 1996 Dec; 83: 1189-92
53. Müller FO, Schall R, Hundt HKL, et al. Pharmacokinetics of aprotinin in two patients with chronic renal impairment. Br J Clin Pharmacol 1996 Jun; 41: 619-20
54. Royston D, Cardigan R, Mackie I, et al. Comparison of plasma aprotinin concentrations using weight related and fixed dose regimen [abstract no. A 273]. Anesthesiology 1998 Sep; 89 (3A) Suppl.
55. Schall R, Groenewoud G, Hundt HKL, et al. Pharmacokinetic profile of aprotinin (Trasylol Rm) in female patients undergoing primary elective hysterectomy. Drug Invest 1992; 4 (4): 292-9
56. Schall R, Müller FO, Hundt HKL, et al. Pharmacokinetic profile of high doses of aprotinin in patients undergoing primary elective hysterectomy: a meta-analysis of two clinical trials. Drug Invest 1994 Apr; 7: 200-8
57. Royston D. Blood-sparing drugs: aprotinin, tranexamic acid, and -aminocaproic acid. Int Anesthesiol Clin 1995 Winter; 33: 155-79
58. Davies MJ, Allen A, Kort H, et al. Prospective, randomized, double-blind study of high-dose aprotinin in pediatric cardiac operations. Ann Thorac Surg 1997 Feb; 63: 497-503
59. D'Ambra MN, Akins CW, Blackstone EH, et al. Aprotinin in primary valve replacement and reconstruction: a multicenter, double-blind, placebo-controlled trial. J Thorac Cardiovasc Surg 1996; 112 (4): 1081-9
60. Lemmer Jr JH, Dilling EW, Morton JR, et al. Aprotinin for primary coronary artery bypass grafting: a multicenter trial of three dose regimens. Ann Thorac Surg 1996 Dec; 62: 1659-68
61. Levy JH, Pifarre R, Schaff HV, et al. A multicenter, doubleblind, placebo-controlled trial of aprotinin for reducing blood loss and the requirement for donor-blood-transfusion in patients undergoing repeat coronary artery bypass grafting. Circulation 1995 Oct 15; 92: 2236-44
62. Ray MJ, O'Brien MF, Hawson GAT. A comparison of the relative efficiency of high and low dose aprotinin in their reduction of blood loss after cardiopulmonary bypass surgery [abstract]. Thromb Haemost 1997 Jun Suppl.: 441
63. Bennett-Guerrero E, Sorohan JG, Gurevich ML, et al. Cost-benefit and efficacy of aprotinin compared with aminocaproic acid in patients having repeated cardiac operations: a randomised, blinded clinical trial. Anesthesiology 1997 Dec; 87: 1373-80
64. Eberle B, Mayer E, Hafner G, et al. High-dose aminocaproic acid versus aprotinin:antifibrinolytic efficacy in first-time coronary operations. Ann Thorac Surg 1998; 65: 667-73
65. Penta de Peppo AP, Pierri MD, Scafuri A, et al. Intraoperative antifibrinolysis and blood-saving techniques in cardiac surgery: prospective trial of 3 antifibrinolytic drugs. Tex Heart Inst J 1995; 22 (3): 231-6
66. Mongan PD, Brown RS, Thwaites BK. Tranexamic acid and aprotinin reduce postoperative bleeding and transfusions during primary coronary revascularisation. Anesth Analg 1998; 87: 258-65
67. Wong BI, McLean RF, Fremes SE, et al. Aprotinin & tranexamic acid for complex open-heart surgery [abstract]. Anesth Analg 1995 Apr; 80 Suppl.: SCA-13
68. Bayer Corporation.. Trasylol: pooled analysis of relative risk of re-operations in patients undergoing CABG - a comparison of full Trasylol dose to placebo. Data on file, 1997
69. Landymore RW, Murphy JT, Lummis H, et al. The use of low- dose aprotinin, -aminocaproic acid or tranexamic acid for prevention of mediastinal bleeding in patients receiving aspirin before coronary artery bypass operations. Eur J Cardiothorac Surg 1997 Apr; 11: 798-800
70. Gilron I, Ralley FE, DeVarennes B, et al. Coronary reoperation with aprotinin, tranexamic acid or placebo: effects on blood loss, outcome and cost [abstract]. Can J Anaesth 1995 May; 42 (Pt 2): A3
71. Pugh SC, Wielogorski AK. A comparison of the effects of tranexamic acid and low-dose aprotinin on blood loss and homologous blood usage in patients undergoing cardiac surgery. J Cardiothorac Vasc Anesth 1995 Jun; 9: 240-4
72. Gschossmann J, Pracki P, Struck E. Efficacy of aprotinin in different doses and autologous blood transfusions in cardiac surgery. Cardiovasc Surg 1994 Dec; 2: 716-9
73. Weber C, Kalmar P, Pokar H. Safely and efficacy of aprotinin in open heart surgery: dose comparison study of full vs half Hammersmith-dosage [abstract]. Anesth Analg 1995 Apr; 80 Suppl.: SCA-117
74. Dietrich W, Schöpf K, Spannagl M, et al. Influence of high- and low-dose aprotinin on activation of hemostasis in open heart operations. Ann Thorac Surg 1998; 65: 70-8
75. D'Errico CC, Shayevitz JR, Martindale SJ, et al. The efficacy and cost of aprotinin in children undergoing reoperativc open heart surgery. Anesth Analg 1996 Dec; 83: 1193-9
76. Gomar C, del Pozo D, Fita G, et al. Aprotinin in paediatric cardiac surgery: Hood loss and use of blood products [abstract]. Br J Anaesth 1995 Jun; 74 Suppl. 2: 33
77. Miller BE, Tosone SR, Tam VKH, et al. Hematologic and economic impact of aprotinin in reoperative pediatric cardiac operations. Ann Thorac Surg 1998; 66: 535-41
78. Carrel TP, Schwanda M, Vogt PR, et al. Aprotinin in pediatric cardiac operations: a benefit in complex malformations and with high-dose regimen only. Ann Thorac Surg 1998; 66: 153-8
79. Able ME, Tilly DA. The effect on costs of the use of half-dose aprotinin for first time reoperative coronary artery bypass patients. Clin Ther 1998; 20 (3): 581-91
80. Lazzara RR, Kidwell FE, Kraemer MF, et al. Reduction in costs, blood products, and operating time in patients undergoing open heart surgery. Arch Surg 1997 Aug; 132: 858-61
81. Sun GE, Hatton RC, Lockwood A, et al. Clinical outcomes and costs of cardiothoracic surgery before and after the availability of aprotinin. Hosp Pharm 1997; 32 (2): 203-9
82. Lathi KG, Hariawala M, Fotouhi F, et al. Economics of aprotinin in cardiac surgery [abstract]. Anesth Analg 1995 Apr; 80 Suppl.: SCA119
83. Van Norman G, Lu J, Spiess B, et al. Aprotinin versus aminocaproic acid in moderate-to-high-risk cardiac surgery: relative efficacy and costs. Anesth Analg 1995 Apr; 80 Suppl.: SCA-19
84. Viravan K, Eto K. Evaluation of the efficacy and the cost-effectiveness of aprotinin versus epsilon-aminocaproic acid in blood conservation in cardiac surgery [abstract]. Int Pharm Abstr 1995 Nov 15; 32: 2340
85. Gott JP, Cooper WA, Schmidt Jr FE, et al. Modifying risk for extracorporeal circulation: trial of four antiinflammatory strategies. Ann Thorac Surg 1998; 66: 747-54
86. Levy JH, Ramsay JG, Murkin J. Aprotinin reduces the incidence of strokes following cardiac surgery [abstract]. Circulation 1996 Oct 15; 94 Suppl.: 1-535
87. Bayer Corporation. Aprotinin prescribing information. West Haven, Connecticut, USA
88. Bidstrup BP, Harrison J, Royston D, et al. Aprotinin therapy in cardiac operations: a report on use in 41 cardiac centers in the United Kingdom. Ann Thorac Surg 1993 Apr; 55: 971-6
89. Dietrich W, Barankay A, Hahnel C, et al. High-dose aprotinin in cardiac surgery: three years' experience in 1,784 patients. J Cardiothorac Vasc Anesth 1992 Jun; 6: 324-7
90. Eberle B, Mayer E, Hafner G, et al. A randomized prospective trial of aprotinin vs. aminocaproic acid: which agent is more effective in suppressing cardiopulmonary bypass-induced fibrinolysis and postoperative chest drainage? [abstract]. Anesthesiology 1995 Sep; 83 Suppl: abstr.110
91. Bidstrup BP, Underwood SR, Sapsford RN, et al. Effect of aprotinin (Trasylol) on aorta-coronary bypass graft patency. J Thorac Cardiovasc Surg 1993 Jan; 105: 147-52
92. Lemmer Jr JH, Stanford W, Bonney SL, et al. Aprotinin for coronary bypass operations: Efficacy, safety, and influence on early saphenous vein graft patency: a multicenter, randomized, double-blind, placebo-controlled study. J Thorac Cardiovasc Surg 1994; 107: 543-53
93. Laub GW, Riebman JB, Chen C, et al. The impact of aprotinin on coronary artery bypass graft patency. Chest 1994 Nov; 106: 1370-5
94. Ray MJ, Marsh NA, Mengerson K. A brief review of studies evaluating the adverse effects of aprotinin therapy in aortocoronary bypass surgery. Thromb Haemost 1997 May; 77: 1038-40
95. Lass M, Simic O, Ostermeyer J. Re-graft patency and clinical efficacy of aprotinin in elective bypass surgery. Cardiovascular Surgery 1997; 5 (6): 604-7
96. Alderman EL, Levy JH, Rich JB, et al. Analyses of coronary graft patency after aprotinin use: results from the International Multicenter Aprotinin Graft Patency Experience (IMAGE) trial. J Thorac Cardiovasc Surg 1998; 116: 716-30
97. Smith PK, Muhlbaier LH. Aprotinin: safe and effective only with the full-dose regimen. Ann Thorac Surg 1996; 62 (6): 1575-7
98. Bayer Corporation.. Analysis on mortality and risk of myocardial infarction. Data on file, 1998
99. Weipert J, Meisner H, Jochum M, et al. Long-term follow-up of aprotinin-specific immunoglobulin G antibodies after cardiac operations. J Thorac Cardiovasc Surg 1997; 114 (4): 676-8
100. Pfannschmidt J, Steeg D, Jugert F. Routine intraoperative application of high-dose aprotinin in open heart surgery in adults: antibody formation after first exposure. Curr Med Res Opin 1995; 13 (5): 282-4
101. Bayer Corporation. Trasylol R prescribing information. West Haven, Connecticut, USA
102. Dietrich W, Späth P, Ebell A, et al. Prevalence of anaphylactic reactions to aprotinin: analysis of two hundred forty-eight reexposures to aprotinin in heart operations. J Thorac Cardiovasc Surg 1997 Jan; 113: 194-201
103. Diefenbach C, Abel M, Limpers B, et al. Fatal anaphylactic shock after aprotinin reexposure in cardiac surgery. Anesth Analg 1995 Apr; 80: 830-1
104. Cottineau C, Moreau X, Druet M, et al. Anaphylactic shock during use of high-dose aprotinin in cardiac surgery. Ann Fr Anesth Reanim 1993 Jan 1; 12: 590-3
105. Dewachter P, Mouton C, Masson C, et al. Anaphylactic reaction to aprotinin during cardiac surgery. Anaesthesia 1993 Dec 1; 48: 1110-1
106. Schulze K, Graeter T, Schaps D, et al. Severe anaphylactic shock due to repeated application of aprotinin in patients following intrathoracic aortic replacement. Eur J Cardiothorac Surg 1993 Aug 1; 7: 495-6
107. Wuthrich B, Schmid P, Schmid ER, et al. IgE-mediated anaphylactic reaction to aprotinin during anaesthesia. Lancet 1992 Jul 18; 340: 173-4
108. Schuler TM, Frosch PJ, Arza D, et al. Allergie vom Soforttyp. Anaphylaktishce reaktion auf Aprotinin. Munch Med Wochenschr 1987 Nov; 129: 816-7
109. La-Ferla GA, Murray WR. Case report. BMJ 1984 Nov 3; 289: 1176
110. Feindt PR, Walcher S, Volkmer I, et al. Effects of high dose aprotinin on renal function in aortocoronary bypass grafting. Ann Thorac Surg 1995 Oct; 60: 1076-80
111. Fraedrich G, Neukamm K, Schneider T, et al. Safety and risk/ benefit assessment of aprotinin in primary CABG. In: Friedel N, Hetzer R, Royston D, editors. Blood use in cardiac surgery. New York: Springer-Verlag, 1991: 221-31
112. Barrons RW, Jahr JS. A review of post-cardiopulmonary bypass bleeding, aminocaproic acid, tranexamic acid, and aprotinin. Am J Ther 1996 Dec; 3: 821-38
113. Ruskowski H, Joos A, Kiefer H, et al. Untersuchungen zur Anti-genitat von Trasylol in der Offenen Herzchirurgie. J Thorac Cardiovasc Surg 1993; 41: 86
114. Stadler PJW, Hübner GE, Koch R-C, et al. Application of safety measures in the production of Trasylol concerning bovine spongiform encephalopathy. J Biotechnol Healthcare 1996; 3 (1): 61-9
115. Hubner GE, Koch R-C, Sprenger KBG, et al. Examination of the biological safety of a drug derived from mammalian organs. Arzneimittel Forschung 1996; 46 (1): 657-61
116. Goelker CF, Whiteman MD, Gugel KH, et al. Reduction of the infectivity of scrapie agent as a model for BSE in the manufacturing process of Trasylol. Biologicals 1996; 24: 103-11
117. Goelker CF, Whiteman MD, Gugel KH, et al. Reduction of the infectivity of scrapic agent as a model for BSE in the manufacturing process of TrasylolR. Biologicals 1996; 24 (2): 103-11
118. Lemmer Jr JH, Metzdorff MT, Krause AH, et al. Aprotinin use in patients with dialysis-dependent renal failure undergoing cardiac operations. J Thorac Cardiovasc Surg 1996 Jul; 112: 192-4
119. Stover EP, Siegel LC, Parks R, et al. Variability in transfusion practice for coronary artery bypass surgery persists despite national consensus guidelines: a 24-institution study. Anesthesiology 1998; 88: 327-33
120. Cooley DA. Conservation of blood during cardiovascular surgery. Am J Surg 1995 Dec; 170 (6A Suppl): 53S-9S
121. Laupacis A, Fergusson D, International Study of Peri-operative Transfusion (ISPOT) Investigators. Drugs to minimize peri-operative blood loss in cardiac surgery: meta-analyses using perioperative Wood transfusion as the outcome. Anesth Analg 1997 Dec; 85: 1258-67
122. Hardy J-F, Bélisle S. Natural and synthetic antifibrinolytics: inert, poisonous or therapeutic agents? Can J Anaesth 1997 Sep; 44: 913-5
123. Fremes SE, Wong BI, Lee E, et al. Metaanalysis of prophylactic drug treatment in the prevention of postoperative bleeding. Ann Thorac Surg 1994; 58 (6): 1580-8
124. Royston D. Coagulation in cardiac surgery. Adv Card Surg 1996; 8: 19-45